Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Dr Chris Bremer commences as Neurizon Chief Executive Officer Highlights: ? Dr Chris Bremer has commenced as Chief Executive Officer, marking an...
Dr Chris Bremer commences as Neurizon CEO
Filed with ASX · · 3 pages · English
Release
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Change of Director's Interest Notice
- Notification of cessation of securities - NUZ
- Neurizon Announces Partial Redemption of Convertible Notes
- Application for quotation of securities - NUZ
- NIH funds Expanded Access Program for NUZ-001 in ALS
Later from Neurizon Therapeutics
- FDA Type C Feedback, HEALEY trial potentially registrational
- Updated Investor Presentation and Webinar Reminder
- Change of AGM Date
- Notice of Annual General Meeting/Proxy Form
- Appendix 4C & Quarterly Update
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics